LXRX News and Press, Lexicon Pharmaceuticals Inc. From 10/27/20

THE WOODLANDS, Texas, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2020 financial results on Thursday, October 29, 2020 before the markets open. Management will conduct a conference call and live webcast at 8:00 a.m. ...

Lexicon Pharmaceuticals (LXRX) inks a private exchange agreement with a holder of its 5.25% Convertible Senior Notes due 2021.The Company will exchange $62.55M of 2021 in aggregate amount of notes for $41.03M in cash (including $1.07M of accrued interest) pl...

THE WOODLANDS, Texas, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has entered into separate, privately-negotiated exchange agreements with certain holders of its 5.25% Convertible Senior Notes due 2021 under which such holders ...

Calithera signals terminating partnership with Incyte Calithera Biosciences Inc. ( CALA ) reported that it has sent a written intimation to Incyte ( INCY ) terminating their collaboration and licensing agreement. The termination will be effective from September 30. The companies had entere...

Lexicon Receives $160.4 Million at Closing Eligible for Up to $65 Million in Milestone Payments Plus Mid-Teens Royalties on Net Sales of XERMELO in Biliary Tract Cancer Substantial Debt Reduction with Full Repayment of Secured Loan THE WOODLANDS, Texas, Sept. 08, 2020 (GLO...

Lexicon Pharmaceuticals  (NASDAQ: LXRX ) commences patient dosing with blinded study drug in its RELIEF-DPN-1, a Phase 2 study of LX9211 for the treatment of diabetic peripheral neuropathic pain. More news on: Lexicon Pharmaceuticals, Inc., Healthcare stocks news, Read more ......

THE WOODLANDS, Texas, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the commencement of patient dosing with blinded study drug in RELIEF-DPN-1, a Phase 2 randomized, placebo-controlled, multi-center clinical study of LX9211 for the trea...

THE WOODLANDS, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following conferences: Citi 15 th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020 Wells Fargo 2020 Virtual Healthcare Co...

Private equity shop GTCR announces that portfolio company TerSera Therapeutics LLC has agreed to acquire Xermelo (telotristat ethyl) from Lexicon Pharmaceuticals (NASDAQ: LXRX ) for ~$159M plus milestones for a new indication. More news on: Lexicon Pharmaceuticals, Inc., Healthcare sto...

CHICAGO , Aug. 3, 2020 /PRNewswire/ -- GTCR, a leading private equity firm, announced today that its TerSera Therapeutics LLC ("TerSera") portfolio company has entered into a definitive agreement to acquire the product Xermelo® (telotristat ethyl) from Lexicon Pharmaceuticals, Inc. (...